论文部分内容阅读
目的探讨卷曲霉素联合莫西沙星治疗耐多药肺结核患者的临床效果。方法选取2013年8月至2015年8月锦州市传染病医院收治的80例耐多药肺结核患者作为研究对象,按随机数字表法将其分为对照组和观察组,各40例。对照组患者运用莫西沙星进行治疗,观察组患者在对照组基础上肌内注射卷曲霉,比较两组患者的临床疗效、空洞闭合情况及不良反应发生情况。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);观察组患者治疗后空洞闭合率明显高于对照组,差异有统计学意义(P<0.05)。结论对于耐多药肺结核患者采用莫西沙星联合卷曲霉素治疗可以有效提升病灶吸收率和空洞闭合率,保证治疗效果,且安全性较高。
Objective To investigate the clinical effect of capreomycin combined with moxifloxacin in the treatment of multidrug-resistant pulmonary tuberculosis patients. Methods Eighty MDR-TB patients admitted to Jinzhou Infectious Disease Hospital from August 2013 to August 2015 were selected as the research objects and divided into control group and observation group according to random number table method, 40 cases each. Patients in the control group were treated with moxifloxacin. The patients in the observation group were intramuscularly injected with Aspergillus oryzae on the basis of the control group, and the clinical efficacy, cavity closure and adverse reactions were compared between the two groups. Results The total effective rate of treatment in observation group was significantly higher than that in control group (P <0.05). The void closure rate in observation group was significantly higher than that in control group (P <0.05) . Conclusion Moxifloxacin and capreomycin can effectively improve the rate of absorption and void closure in patients with multidrug-resistant pulmonary tuberculosis and ensure the therapeutic effect and safety.